.jpeg)
2026-08-26 07:14:21
Bosutinib is a BCR-ABL/SRC tyrosine kinase inhibitor primarily indicated for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This article reviews its established indications, investigational use in autosomal dominant polycystic kidney disease (ADPKD), and critical safety boundaries.
2026-08-26 07:04:50
Revumenib (brand name: REVUFORJ) is a leading oral menin inhibitor designed for relapsed/refractory acute leukemias with KMT2A translocations or NPM1 mutations. This article explores its innovative mechanism of blocking aberrant protein interactions, correcting leukemogenic transcription programs, and outlines key clinical indications and safety management.
2026-08-25 08:20:48
Asciminib (brand name: Scemblix) is the world's first approved BCR-ABL1 allosteric inhibitor, offering a novel treatment option for chronic myeloid leukemia. This guide outlines its targeted mechanism of action, indication-specific dosing, missed-dose protocols, and key safety monitoring points.
2026-08-20 03:28:50
Gilteritinib (brand name XOSPATA) is a highly selective oral FLT3 inhibitor developed by Astellas Pharma, approved for FLT3-mutated relapsed or refractory acute myeloid leukemia (AML). This article provides a structured overview of the drug's development and manufacturing background, the standard 28-day dosing cycle, individualized treatment duration decisions, efficacy assessment milestones, dose-modification and interruption protocols, and practical daily-life management guidance to help patients and families plan treatment schedules and follow-up visits effectively.
2026-08-19 06:01:50
Anagrelide (Anagrelide) is a platelet-reducing agent widely used in essential thrombocythemia. Prolonged use may involve cardiovascular, gastrointestinal, and neurological adverse effects. This article provides a systematic overview of its safety profile and key points for long-term medication management.
2026-08-19 04:31:49
Anagrelide and hydroxyurea are both widely used cytoreductive agents for essential thrombocythemia (ET). They differ in mechanism of action, vascular event prevention, adverse effect profiles, and long-term therapeutic positioning. This article provides a comprehensive comparison to guide individualized treatment decisions.
2026-08-18 04:30:05
SCEMBLIX (asciminib) is the first BCR-ABL1 myristoyl pocket allosteric inhibitor for chronic myeloid leukemia. This guide covers common side effects, dosing in hepatic/renal impairment, cardiovascular monitoring, drug interactions, and pregnancy risk.
2026-08-13 04:02:58
Asciminib (brand name SCEMBLIX) is the first STAMP-class targeted therapy for chronic myeloid leukemia. This article clarifies nomenclature consistency, strict fasting requirements, missed-dose protocols, and safety monitoring essentials to help patients avoid medication errors and optimize therapeutic outcomes.
2026-08-12 04:11:20
Enasidenib (brand name IDHIFA) is an oral, selective IDH2 inhibitor indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation. This article covers its indications, dosing, adverse effects, mechanism of action, storage, and special-population considerations.
2026-08-11 06:06:06
Midostaurin and gilteritinib are both FLT3-targeted agents but differ fundamentally in selectivity, indications, and treatment phase. This article systematically compares their mechanisms, clinical roles, and appropriate use contexts in precision AML management.
2026-08-10 06:39:28
Belumosudil (Rezurock) is a selective ROCK2 inhibitor approved for chronic graft-versus-host disease. This article explains the expected timeline, efficacy assessment, and realistic goals when treating pulmonary cGVHD.
2026-08-07 06:49:51
Tazemetostat is the world's first approved oral EZH2 methyltransferase inhibitor, targeting epigenetic dysregulation in follicular lymphoma and epithelioid sarcoma. This article provides a comprehensive overview of its mechanism of action, approved indications, efficacy data, standard starting and maintenance dosing, dose modification protocols, and the critical safety alert regarding its global market withdrawal in March 2026 due to secondary hematologic malignancy risk.
